An inhibitor of BMP receptors ALK1, ALK2, ALK3, and ALK6
Related Products
Alternative(s)
11802LDN-193189
Contained In
44676Hepatocyte Maintenance Reagent Set
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

LDN-193189 (hydrochloride)

Item No. 19396

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline, dihydrochloride
CAS Number
1435934-00-1
Synonyms
  • DM-3189
Molecular Formula
C25H22N6 • 2HCl
Formula Weight
479.4
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 2 mg/ml
λmax
235, 290, 387 nm
SMILES
N1(C2=CC=C(C(C=N3)=CN4C3=C(C5=CC=NC6=C5C=CC=C6)C=N4)C=C2)CCNCC1.Cl.Cl
InChi Code
InChI=1S/C25H22N6.2ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30;;/h1-10,15-17,26H,11-14H2;2*1H
InChi Key
CMQXLLAILGGLRV-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $30

    Add

    5 mg

    $68

    Add

    10 mg

    $119

    Add

    25 mg

    $224

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM.1 In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively).2 LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.3,4 This product is also available as part of Cayman's Hepatocyte Maintenance Reagent Kit (Item No. 44676).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cuny, G.D., Yu, P.B., Laha, J.K., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg. Med. Chem. Lett. 18(15), 4388-4392 (2008).

    2. Sanvitale, C.E., Kerr, G., Chaikuad, A., et al. A new class of small molecule inhibitor of BMP signaling. PLoS One 8(4), 62721 (2013).

    3. Yu, P.B., Deng, D.Y., Lai, C.S., et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 14(12), 1363-1369 (2008).

    4. Lee, Y.C., Cheng, C.J., Bilen, M.A., et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 71(15), 5194-5203 (2011).